Cargando…
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
In June 2011, the US Food and Drug Administration approved belatacept for the prophylaxis of organ rejection in adult kidney transplant recipients. This review discusses the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. Belatacept is a se...
Autores principales: | Wojciechowski, David, Vincenti, Flavio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496190/ https://www.ncbi.nlm.nih.gov/pubmed/23152668 http://dx.doi.org/10.2147/BTT.S23561 |
Ejemplares similares
-
Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017) -
Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation
por: Zhang, Hengcheng, et al.
Publicado: (2021) -
Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020) -
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti, Giovanbattista, et al.
Publicado: (2012) -
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
por: Gupta, Gaurav, et al.
Publicado: (2010)